Howard Michael T, Anderson Christine B, Fass Uwe, Khatri Shikha, Gesteland Raymond F, Atkins John F, Flanigan Kevin M
Department of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA.
Ann Neurol. 2004 Mar;55(3):422-6. doi: 10.1002/ana.20052.
We report the translational readthrough levels induced by the aminoglycosides gentamicin, amikacin, tobramycin, and paromomycin for eight premature stop codon mutations identified in Duchenne's and Becker's muscular dystrophy patients. In a transient transfection reporter assay, aminoglycoside treatment results show that one stop codon mutation is suppressed significantly better (up to 10% stop codon readthrough) than the others; five show lower but statistically significant suppression (< 2% stop codon readthrough); and two appear refractory to aminoglycoside treatment. Readthrough levels do not substantially vary between different sources of gentamicin, and, for this set of mutations, the efficiency of termination at the premature stop codon mutation does not appear to correlate with disease severity.
我们报告了庆大霉素、阿米卡星、妥布霉素和巴龙霉素这几种氨基糖苷类药物对杜氏和贝克氏肌营养不良患者中鉴定出的8种过早终止密码子突变所诱导的翻译通读水平。在瞬时转染报告基因检测中,氨基糖苷类药物处理结果显示,一种终止密码子突变的抑制效果明显优于其他突变(高达10%的终止密码子通读);五种显示出较低但具有统计学意义的抑制(<2%的终止密码子通读);还有两种似乎对氨基糖苷类药物治疗无反应。不同来源的庆大霉素之间的通读水平没有显著差异,并且对于这组突变,过早终止密码子突变处的终止效率似乎与疾病严重程度无关。